{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T20:40:08Z","timestamp":1750538408767,"version":"3.41.0"},"reference-count":8,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Clin Nucl Med"],"published-print":{"date-parts":[[2022,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Herein, we present a 72-year-old woman with metastatic thymic carcinoma, referred for salvage peptide receptor radionuclide therapy with <jats:sup>177<\/jats:sup>Lu-DOTATATE after completing all treatment options according to current clinical practice and guidelines. However, the patient was not eligible for <jats:sup>177<\/jats:sup>Lu-DOTATATE peptide receptor radionuclide therapy and underwent <jats:sup>68<\/jats:sup>Ga-FAPI04 PET\/CT to assess the potential for a FAP-targeted therapy.<\/jats:p>","DOI":"10.1097\/rlu.0000000000003843","type":"journal-article","created":{"date-parts":[[2021,8,15]],"date-time":"2021-08-15T22:02:33Z","timestamp":1629064953000},"page":"e79-e80","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":4,"title":["Intratumoral Heterogeneity in a Patient With Metastatic Thymic Carcinoma on 18F-FDG, 68Ga-DOTATATE, and 68Ga-FAPI04 PET\/CT"],"prefix":"10.1097","volume":"47","author":[{"given":"Emine G\u00f6knur","family":"Isik","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Serkan","family":"Kuyumcu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zeynep G\u00f6zde","family":"Ozkan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Duygu","family":"Has Simsek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasemin","family":"Sanli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2021,8,13]]},"reference":[{"key":"bib1-20250621","doi-asserted-by":"crossref","first-page":"S304","DOI":"10.1097\/JTO.0b013e3181f20c05","article-title":"Staging system of thymoma","volume":"5","year":"2010","journal-title":"J Thorac Oncol"},{"key":"bib2-20250621","doi-asserted-by":"crossref","first-page":"7607","DOI":"10.21037\/jtd-2019-thym-01","article-title":"Classification and staging of thymoma","volume":"12","year":"2020","journal-title":"J Thorac Dis"},{"key":"bib3-20250621","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1007\/s00259-006-0355-4","article-title":"Peptide receptor radionuclide therapy with 177Lu-octreotate in patients with foregut carcinoid tumours of bronchial, gastric and thymic origin","volume":"34","year":"2007","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib4-20250621","doi-asserted-by":"crossref","first-page":"e278","DOI":"10.1097\/RLU.0000000000000733","article-title":"Thymoma treated with 177Lu DOTATATE induction and maintenance PRRT","volume":"40","year":"2015","journal-title":"Clin Nucl Med"},{"key":"bib5-20250621","doi-asserted-by":"crossref","first-page":"386","DOI":"10.2967\/jnumed.118.215913","article-title":"68Ga-FAPI PET\/CT: biodistribution and preliminary dosimetry estimate of 2 DOTA-containing FAP-targeting agents in patients with various cancers","volume":"60","year":"2019","journal-title":"J Nucl Med"},{"key":"bib6-20250621","doi-asserted-by":"crossref","first-page":"801","DOI":"10.2967\/jnumed.119.227967","article-title":"68Ga-FAPI PET\/CT: tracer uptake in 28 different kinds of cancer","volume":"60","year":"2019","journal-title":"J Nucl Med"},{"key":"bib7-20250621","doi-asserted-by":"crossref","first-page":"e141","DOI":"10.1097\/RLU.0000000000003489","article-title":"Fibroblast activation protein inhibitor PET\/CT: a promising molecular imaging tool","volume":"46","year":"2021","journal-title":"Clin Nucl Med"},{"key":"bib8-20250621","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1097\/RLU.0000000000003667","article-title":"Safety of fibroblast activation protein-targeted radionuclide therapy by a low-dose dosimetric approach using 177Lu-FAPI04","volume":"46","year":"2021","journal-title":"Clin Nucl Med"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000003843","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T20:06:43Z","timestamp":1750536403000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000003843"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,13]]},"references-count":8,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000003843","relation":{},"ISSN":["1536-0229","0363-9762"],"issn-type":[{"type":"electronic","value":"1536-0229"},{"type":"print","value":"0363-9762"}],"subject":[],"published":{"date-parts":[[2021,8,13]]}}}